NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 390, 2627–2642 (2017).

Article  Google Scholar 

Kovesdy, C. P. Epidemiology of chronic kidney disease: an update 2022. Kidney Int. Suppl. 12, 7–11 (2022).

Article  Google Scholar 

Eckel, R. H. & Cornier, M. A. Update on the NCEP ATP-III emerging cardiometabolic risk factors. BMC Med. 12, 115 (2014).

Article  PubMed  Google Scholar 

Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606–1635 (2023).

Article  PubMed  Google Scholar 

Tchernof, A. & Després, J. P. Pathophysiology of human visceral obesity: an update. Physiol. Rev. 93, 359–404 (2013).

Article  CAS  PubMed  Google Scholar 

Ye, C. et al. Causal associations of obesity with chronic kidney disease and arterial stiffness: a mendelian randomization study. J. Clin. Endocrinol. Metab. 107, e825–e835 (2022).

Article  PubMed  Google Scholar 

Chang, A. R. et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ 364, k5301 (2019). This meta-analysis demonstrates that increased BMI is an independent risk factor for GFR decline and death in the general population and those with CKD.

Article  PubMed  Google Scholar 

Hsu, C. Y., McCulloch, C. E., Iribarren, C., Darbinian, J. & Go, A. S. Body mass index and risk for end-stage renal disease. Ann. Intern. Med. 144, 21–28 (2006).

Article  PubMed  Google Scholar 

Zhang, S. Y. et al. Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight. Cell Metab. 35, 875–886.e5 (2023). This study demonstrates that metformin mediates weight loss through a kidney GDF15-dependent area postrema axis.

Article  CAS  PubMed  Google Scholar 

Weisinger, J. R., Kempson, R. L., Eldridge, F. L. & Swenson, R. S. The nephrotic syndrome: a complication of massive obesity. Ann. Intern. Med. 81, 440–447 (1974).

Article  CAS  PubMed  Google Scholar 

D’Agati, V. D., Fogo, A. B., Bruijn, J. A. & Jennette, J. C. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am. J. Kidney Dis. 43, 368–382 (2004).

Article  PubMed  Google Scholar 

Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J. & D’Agati, V. D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59, 1498–1509 (2001).

Article  CAS  PubMed  Google Scholar 

Chen, H. M. et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am. J. Kidney Dis. 48, 772–779 (2006).

Article  PubMed  Google Scholar 

Chen, H. M. et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am. J. Kidney Dis. 52, 58–65 (2008).

Article  PubMed  Google Scholar 

D’Agati, V. D. et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat. Rev. Nephrol. 12, 453–471 (2016).

Article  PubMed  Google Scholar 

Praga, M. et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol. Dial. Transpl. 16, 1790–1798 (2001).

Article  CAS  Google Scholar 

Serra, A. et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 73, 947–955 (2008).

Article  CAS  PubMed  Google Scholar 

Griffin, K. A., Kramer, H. & Bidani, A. K. Adverse renal consequences of obesity. Am. J. Physiol. Ren. Physiol. 294, F685–F696 (2008).

Article  CAS  Google Scholar 

Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z. & Hall, M. E. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ. Res. 116, 991–1006 (2015).

Article  CAS  PubMed  Google Scholar 

Schorr, U., Blaschke, K., Turan, S., Distler, A. & Sharma, A. M. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J. Hypertens. 16, 1475–1480 (1998).

Article  CAS  PubMed  Google Scholar 

Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z. & Hall, M. E. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat. Rev. Nephrol. 15, 367–385 (2019).

Article  PubMed  Google Scholar 

Goodfriend, T. L., Ball, D. L., Egan, B. M., Campbell, W. B. & Nithipatikom, K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43, 358–363 (2004).

Article  CAS  PubMed  Google Scholar 

Jeon, J. H. et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 22, 1502–1511 (2008).

Article  CAS  PubMed  Google Scholar 

Mallamaci, F. et al. ACE inhibition is renoprotective among obese patients with proteinuria. J. Am. Soc. Nephrol. 22, 1122–1128 (2011).

Article  CAS  PubMed  Google Scholar 

Kim, S. et al. The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system. J. Biomed. Biotechnol. 2006, 27012 (2006).

Article  PubMed  Google Scholar 

Henegar, J. R. et al. Catheter-based radiorefrequency renal denervation lowers blood pressure in obese hypertensive dogs. Am. J. Hypertens. 27, 1285–1292 (2014).

Article  CAS  PubMed  Google Scholar 

Xu, X., Huang, X., Zhang, L., Qin, Z. & Hua, F. Adiponectin protects obesity-related glomerulopathy by inhibiting ROS/NF-κB/NLRP3 inflammation pathway. BMC Nephrol. 22, 218 (2021).

Article  CAS  PubMed  Google Scholar 

Hall, J. E. et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J. Biol. Chem. 285, 17271–17276 (2010).

Article  CAS  PubMed  Google Scholar 

Mansukhani, M. P., Wang, S. & Somers, V. K. Chemoreflex physiology and implications for sleep apnoea: insights from studies in humans. Exp. Physiol. 100, 130–135 (2015).

Article  PubMed  Google Scholar 

Hall, M. E. et al. Obesity, hypertension, and chronic kidney disease. Int. J. Nephrol. Renovasc Dis. 7, 75–88 (2014).

Article  PubMed  Google Scholar 

Eddy, A. A. & Fogo, A. B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J. Am. Soc. Nephrol. 17, 2999–3012 (2006).

Article  CAS  PubMed  Google Scholar 

Benomar, Y. et al. Central resistin overexposure induces insulin resistance through Toll-like receptor 4. Diabetes 62, 102–114 (2013).

Article  CAS  PubMed  Google Scholar 

Yano, Y. et al. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J. Clin. Hypertens. 9, 775–782 (2007).

Article  CAS  Google Scholar 

Sharma, K. et al. Adiponectin regulates albuminuria and podocyte function in mice. J. Clin. Invest. 118, 1645–1656 (2008).

CAS  PubMed  Google Scholar 

Fang, F. et al. Deletion of the gene for adiponectin accelerates diabetic nephropathy in the Ins2+/C96Y mouse. Diabetologia 58, 1668–1678 (2015).

Article  CAS  PubMed  Google Scholar 

Ohashi, K. et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler. Thromb. Vasc. Biol. 27, 1910–1917 (2007).

Article  CAS  PubMed  Google Scholar 

Briffa, J. F., McAinch, A. J., Poronnik, P. & Hryciw, D. H. Adipokines as a link between obesity and chronic kidney disease. Am. J. Physiol. Ren. Physiol. 305, F1629–F1636 (2013).

Article  CAS  Google Scholar 

Aizawa-Abe, M. et al. Pathophysiological role of leptin in obesity-related hypertension. J. Clin. Invest. 105, 1243–1252 (2000).

Article  CAS  PubMed  Google Scholar 

Huby, A. C. et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 132, 2134–2145 (2015).

Article  CAS  PubMed  Google Scholar 

Belin de Chantemèle, E. J., Mintz, J. D., Rainey, W. E. & Stepp, D. W. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension 58, 271–279 (2011).

Article  PubMed  Google Scholar 

de Vries, A. P. et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2, 417–426 (2014).

Article